University of Minnesota. Driven to Discover.
Both AAP and the CDC, though, support using FluMist with the goal of optimizing vaccine coverage.
ACIP suggests vaccination by the end of October—but the start date is less clear.
After careful deliberation, experts approved the nasal-spray vaccine 12-2.
Overall flu vaccine effectiveness was 48%, but a change in the 2009 H1N1 vaccine strain didn't fix the problem with the inhaled vaccine's effectiveness in children.
Experts hope the lack of a nasal-spray vaccine doesn't dampen recent advances in kids.
In an emotional vote, CDC advisors recommend against using the nasal spray vaccine.
The initial effectiveness investigations flagged a problem with the 2009 H1N1 vaccine virus in the inhaled version and drove improvement efforts.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.